Bli medlem
Bli medlem

Du är här


Elekta: The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment

Pioneer in uniting imaging technology with radiotherapy to explore
potential of MRI to refine tumor targeting

MANCHESTER, England, July 22, 2014 - Elekta (NSE:EKTAb) and Royal
Philips (NYSE:PHG, AEX:PHIA) announced today that The Christie NHS
Foundation Trust (Manchester, UK), a specialist cancer center, will
join a consortium whose mission is to develop the clinical value of
an integrated magnetic resonance imaging (MRI) guided radiation
therapy system. Such a system would, in principle, improve the
practice of radiotherapy via real-time visualization of cancer

"The Christie was an essential participant in the project 14 years ago
that laid the foundations of the use of cone beam computed tomography
[CBCT] at the time of treatment to improve radiotherapy delivery,"
says Niklas Savander, Elekta President and CEO. "It has a dedicated
team of researchers in medical physics, radiotherapy and clinical
oncology and MR imaging that is committed to the most accurate and
individualized delivery of radiation therapy. The Christie has the
perfect blend of experience and expertise to further help the
consortium make MRI-guided radiation therapy a reality."

The Christie is the seventh member to join the research consortium
that assesses the novel technology, which brings together
state-of-the-art radiation therapy and MRI in a single system. The
consortium also includes the University Medical Center Utrecht
(Utrecht, the Netherlands), The University of Texas MD Anderson
Cancer Center (Houston, Texas), The Netherlands Cancer
Institute-Antoni van Leeuwenhoek Hospital (Amsterdam, the
Netherlands), Sunnybrook Health Sciences Centre (Toronto, Ontario),
The Froedtert & Medical College of Wisconsin Cancer Center
(Milwaukee, Wisconsin) and The Institute of Cancer Research, working
with its clinical partner The Royal Marsden NHS Foundation Trust
(London, England).

"We are very excited to be a part of an international consortium of
truly exceptional centers that are striving as we are to develop
technological innovations to benefit patients," says Dr. Ananya
Choudhury, Consultant and Honorary Senior Clinical Lecturer, Clinical
Oncology at The Christie. "Unlike any imaging modality now in use in
combination with radiotherapy, MRI can provide highly detailed images
of the tumor and surrounding normal tissues. Moreover, MRI will
permit physicians to non-invasively visualize and track the target
during beam delivery - real-time imaging - which will further improve
treatment accuracy."

The Christie joined the recent research consortium meeting at Utrecht,
where the clinical indications that would benefit the most from the
use of MRI-guided radiation therapy were discussed. These targets are
typically going to be in anatomy that changes its position and shape
either from day to day or during the treatment. The consortium
anticipates that the use of MRI imaging at the time of treatment will
result in a considerable increase in the accuracy of the placement of
the dose, reducing the need for large safety margins around the tumor

"When we first started this journey with Elekta and the University
Medical Center Utrecht more than a decade ago, we already had a clear
vision, yet we could only dream of today's MRI imaging performance,"
says Gene Saragnese, CEO Imaging Systems at Philips Healthcare.
"Since then we have come a long way and I am convinced that with the
current state of the technology and the growing consortium of leaders
in radiation therapy delivery, we have the prerequisites to make the
integrated MRI-guided radiation therapy technology a game changer in
cancer care."

The MRI-guided radiation therapy system is a works in progress and not
available for sale or distribution.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta

Tel: +31 653 561 242, e-mail:
Time zone: CET: Central European Time
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail:
Time zone: CET: Central European Time

Steve Klink, Philips Group Communications
Tel: +31 6 10888824, e-mail:
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public
in accordance with the Securities Market Act and/or the Financial
Instruments Trading Act. The information was published at 07:30 CET
on July 22, 2014.

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The
company develops sophisticated, state-of-the-art tools and treatment
planning systems for radiation therapy, radiosurgery and
brachytherapy, as well as workflow enhancing software systems across
the spectrum of cancer care. Stretching the boundaries of science and
technology, providing intelligent and resource-efficient solutions
that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over
6,000 hospitals worldwide. Elekta employs around 3,500 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on the Nordic Exchange under the ticker
STO:EKTAB. Website:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and
well-being company, focused on improving people's lives through
meaningful innovation in the areas of Healthcare, Consumer Lifestyle
and Lighting. Headquartered in the Netherlands, Philips posted 2013
sales of EUR 23.3 billion and employs approximately 112,000 employees
with sales and services in more than 100 countries. The company is a
leader in cardiac care, acute care and home healthcare, energy
efficient lighting solutions and new lighting applications, as well
as male shaving and grooming and oral healthcare. News from Philips
is located at


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.